Strategic Partners GovSat and Telespazio France to Provide Capabilities for the French Ministry of Defence
With the aim of meeting the needs of the French government, GovSat and Telespazio France pooled their skills, infrastructures and solutions to create a complete catalog of satellite telecommunications services in various military bands. The offer has been selected by the Joint Directorate for Infrastructure Networks and Information Systems (“Direction Interarmées des Réseaux d'Infrastructure et des Systèmes d'Information”, or DIRISI). Under the contract, Telespazio France, supported by GovSat, will begin supplying satellite capacity to all French military and state entities by the end of 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181105005306/en/
Corinne Mailles Deputy General Manager of Telespazio France & Patrick Biewer, CEO of GovSat (Photo: Business Wire)
Patrick Biewer, CEO of GovSat, commented, ”Together with Telespazio France, we are honoured to be serving the French government, using the unique capabilities of the GovSat-1 satellite which was launched earlier this year, as well as Telespazio’s tailor-made service offerings. These new services provide the required level of flexibility, security and mobility, and are the ideal solution to meet the new challenges armies face.”
Corinne Mailles, Deputy General Manager of Telespazio France, emphasizes that “this partnership is also part of a common strategy of value creation and innovation for the benefit of military forces engaged in operations.”
GovSat is a Luxembourg-based satellite operator, created out of a partnership between the Luxembourg government and SES, the world's leading satellite operator. GovSat’s mission is to provide secure, reliable and accessible governmental satellite communication services to address the demand resulting from defence and institutional security applications. The company’s first satellite, GovSat-1, is a multi-mission satellite that uses X-band and Military Ka-band frequencies on high-power and fully steerable mission beams to support multiple operations. Further information is available here: www.govsat.lu
About Telespazio France
Headquartered in Toulouse with offices in Paris, Kourou and Bordeaux, Telespazio France is the French subsidiary of Telespazio, which is part of the Leonardo and Thales groups (67% / 33%). A pioneer in satellite services, the history of Telespazio has been marked by decisive developments and technological breakthroughs for more than 50 years. Telespazio France is a recognized leader in the field of operations. It operates complex satellite systems and maintains numerous infrastructures for CNES, Arianespace and the French Defense. Telespazio France relies on its culture of innovation and on its expertise in new digital technologies to develop new services with high added-value, especially in the fields of telecommunications, geo-information and navigation.
Telespazio, a joint venture between Leonardo (67%) and Thales (33%), is one of the world leaders in satellite services: from the design and development of space systems to the management of launch campaigns, satellites control to earth observation services, integrated communications services to satellite navigation and localization services and scientific programs. Telespazio plays a major role in these markets thanks to its technological heritage and its participation in major European space programs such as Galileo, EGNOS, Copernicus, GMES and COSMO-SkyMed. In 2017, Telespazio generated 564 million sales for a workforce of around 2,500 people in eight countries.
Contact for GovSat:
Melanie Delannoy - Communications and Marketing
Phone: +352 710 725 329
Contact for Telespazio France:
Nicolas Vincent – VP Sales and Marketing
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EET | Tiedote
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EET | Tiedote
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EET | Tiedote
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EET | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EET | Tiedote
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EET | Tiedote
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme